Tagged with GE

Amgen One of the new generation of pharmaceutical general managers in Romania discusses the complexities of introducing innovative therapies on the market and explains how the country has become the ‘to-go-to’ destination for relocating pharma companies’ support services. Amgen has been present in Romania as far back as 2004. Can you…

Zentiva The GM of one of the leading generics companies on the Romanian market shares insights into why generics penetration remains underdeveloped and the importance of having an export strategy and diversified portfolio.   You have been in your current position since 2009, witnessing many changes. Can you introduce Zentiva in…

generics After Brazil, Torrent is looking to strengthen its foothold in the Mexican market. The general manager of the local affiliate explains the opportunities Latin America offers to Indian companies, how – despite an apparent slackening performance – the Mexican pharmaceutical market is growing and how niche is the name of…

generics At Valeant each region has a unique mix of prescription brands, branded generics and OTC products. The general manager for Mexico, Central America, the Caribbean and the Andean region discusses the company’s objectives for Spanish speaking Latin America and how it plans to leverage the recently acquired Bausch+Lomb business to…

Boehringer Ingelheim Javier Castro came from Boehringer Ingelheim’s headquarters to run the Peruvian affiliate in January 2015, bringing with him a wealth of experience necessary to take the company to the next level. He discusses market access, reimbursement and new launches that BI plans to bring to Peru.   What are your…

Ferring The country manager of a research-driven, specialty biopharmaceutical group offering treatments for infertility outlines his firm’s approach for the socially conservative Algerian market. Your promotion as general manager of Ferring Algeria is quite recent. Can you tell us what were your priorities during the first year and how do you…

biosimilars Brothers Juan José and Andrés Aguirre Salazar of Grupo Bruluart talk about the company’s most important milestones and how they are institutionalizing the family business to prepare the firm for new market opportunities. Could you walk us through the most important milestones of the company and provide our readers with…

generics Carlos Leigh, executive president of Peru’s Asociación de Laboratorios Farmacéuticos Latinoamericanos (ALAFAL), discusses the advantages that LATAM companies have over big pharma players looking to enter the Peruvian market, and offers his predictions for the future of the sector for growth. Can you introduce yourself to our readers? I actively worked in…

biotechnology The genomic revolution represents a before and after in the field of medicine. Sistemas Genómicos has understood this back in 1998 and today is the largest private organization offering DNA and RNA sequencing in Spain. The director for Latin America and country manager for Mexico discuss the unmet needs they…

R&D Brian Wang, CEO of Korean super-generics developer GL PharmTech, discusses Korea’s relative strengths in different stages of R&D, and how this motivated the foundation and evolution of GL PharmTech. What was the inspiration that prompted you to found GL PharmTech, a company based on incrementally modified drugs, back in 2002?…

heparin The vice president of Laboratorio Tuteur highlights the position of his company as the leaders in specialty products in Argentina.   Could you please give us an historical overview of Laboratorio Tuteur S.A.C.I.F.I.A., a company with more than 40 years of history? Laboratorio Tuteur S.A.C.I.F.I.A. is a company based in Argentina…

doing business Insights from existing players on what to expect and how to succeed in Algeria today. “The key to being successful is to be direct and forthright with the Algerians themselves. Trust in them and they will certainly trust in you.” – Essam Farouk, CEO, El Kendi. “The pace of doing…